Prostacyclin inhibition by indomethacin aggravates hepatic damage and encephalopathy in rats with thioacetamide-induced fulminant hepatic failure

World Journal of Gastroenterology

Volumn 11, Issue 2, 2005, Pages 232-236

  Chu, Chi Jen ^a,d   Hsiao, Ching Chin ^a,d   Wang, Teh Fang ^b   Chan, Cho Yu ^a,d   Lee, Fa Yauh ^a,d   Chang, Full Young ^a,d   Chen, Yi Chou ^a   Huang, Hui Chun ^a,d   Wang, Sun Sang ^c,d   Lee, Shou Dong ^a,d  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Armed Forces Sung Shan Hospital   (Taiwan)

^c Taipei Municipal Gan Dau Hospital   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Fulminant hepatic failure; Hepatic encephalopathy; Indomethacin; Prostacyclin

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; BILIRUBIN; CREATININE; INDOMETACIN; PLACEBO; PROSTACYCLIN; SODIUM CHLORIDE; THIOACETAMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATIC ENCEPHALOPATHY; INHIBITION KINETICS; LIVER FAILURE; MALE; MEDICAL ASSESSMENT; MORTALITY; MOTOR ACTIVITY; NONHUMAN; RAT;

EID: 19944430667     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i2.232     Document Type: Article

References (46)

1. Gammal SH, Jones EA. Hepatic encephalopathy. Med Clin North Am 1989; 73: 793-813
2. Sherlock S. Fulminant hepatic failure. Adv Intern Med 1993; 38: 245-267
3. Mousseau DD, Butterworth RF. Current theories on the pathogenesis of hepatic encephalopathy. Soc Exp Biol Med 1994; 206: 329-344
4. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333 664-666
5. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994; 20: 1359-1363
6. Lockwood AH, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991; 11: 337-341
7. Janigro D, West GA, Nguyen TS, Winn HR. Regulation of blood-brain barrier endothelial cells by nitric oxide. Circ Res 1994; 75: 528-538
8. 2 formation parallels blood-brain barrier disruption in an experimental rat model of bacterial meningitis. Brain Res Bull 1998; 46: 541-546
9. Smith WL. Prostaglandin biosynthesis and its compartmentation in vascular smooth muscle and endothelial cells. Annu Rev Physiol 1986; 48: 251-262
10. Pizcueta P, Piqué JM, Fernandéz M, Bosch J, Rodés J, Whittle BJ, Moncada S. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103: 1909-1915
11. Lee FY, Albillos A, Colombato LA. Chronic Nω-nitro-L-arginine administration corrects peripheral vasodilation and systemic capillary hypotension, and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology 1993; 17: 84-90
12. Sitzmann JV, Bulkley GB, Mitchell MC, Campbell K. Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension. Ann Surg 1989; 209: 322-327
13. Bruix J, Bosch J, Kravetz D, Mastai R, Rodéz J. Effects of prostacyclin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985; 88: 430-435
14. Chu CJ, Wang SS, Lee FY, Chang FY, Lin HC, Hou MC, Chan CC, Wu SL, Chen CT, Huang HC, Lee SD. Detrimental effects of nitric oxide inhibition on hepatic encephalopathy in rats with thioacetamide-induced fulminant hepatic failure. Eur J Clin Invest 2001; 31: 156-163
15. 2 in carbontetrachloride induced acute hepatic injury in the rat. Prostaglandins 1986; 32: 439-455
16. Araki H, Lefer AM. Cytoprotective actions of prostacyclin during hypoxia in the isolated perfused rat liver. Am J Physiol 1980; 238: H176-H181
17. Davis DC, Potter WZ, Jollow DJ, Mitchell JR. Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen. Life Science 1974; 14: 2099-2103
18. 1 in an experimental massive hepatic cell necrosis model. Hepatology 1987; 7: 1184-1188
19. 2) and a prostaglandin analogue BW245C on galactosamine-induced hepatic necrosis. J Hepatol 1986; 2: 53-64
20. Ogawa M, Mori T, Mori Y, Ueda S, Yoshida H, Kato I, Iesato K, Wakashin Y, Wakashin M, Okuda K. Inhibitory effects of prostaglandin E1 on T-cell mediated cytotoxicity against isolated mouse liver cells. Gastroenterology 1988; 94: 24-30
21. Alp MH, Hickman R. The effect of prostaglandins, branchedchain amino acids and other drugs on the outcome of experimental acute porcine hepatic failure. J Hepatol 1987; 4: 99-107
22. Guarner F, Boughton-Smith NK, Blackwell GJ, Moncada S. Reduction by prostacyclin of acetaminophen-induced toxicity in the mouse. Hepatology 1988; 8: 248-253
23. 2: favor able effects on rat liver injury. Gastroenterology 1992; 102: 572-576
24. Hou MC, Cahill PA, Zhang S, Wang YN, Hendrickson RJ, Redmond EM, Sitzmann JV. Enhanced cyclooxygenase-1 expression within the superior mesenteric artery of portal hypertensive rats: role in the hyperdynamic circulation. Hepatology 1998; 27: 20-27
25. Albrecht J, Hilgier W, Rafalowska U. Activation of arginine metabolism to glutamate in rat brain synaptosomes in thioacetamide-induced hepatic encephalopathy: an adaptive response? J Neurosci Res 1990; 25: 125-130
26. Osada J, Aylagas H, Miro-Obradors MJ, Arce C, Palacios-Alaiz E, Cascales M. Effect of acute thioacetamide administration on brain phospholipid metabolism. Neurochem Res 1990; 15: 927-931
27. A-benzodiazepine receptor on hepatic encephalopathy in the rat: comparison with uremic encephalopathy. Hepatology 1991; 14: 963-968
28. Bengtsson F, Gage FH, Jeppsson B, Nobin A, Rosengren E. Brain monoamine metabolism and hehaviour in portacaval shunted rats. Exp Neurol 1985; 90: 21-35
29. Ribeiro J, Nordlinger B, Ballet F, Cynober L, Coudray-Lucas C, Baudrimont M, Legendre C, Dilelo R, Panis Y. Intrasplenic hepatocellular transplantation corrects hepatic encephalopathy-in portacaval-shunted rats. Hepatology 1992; 15 12-18
30. Chu CJ, Lee FY, Wang SS, Chang FY, Lin HS, Wu SL, Chan CC, Tsai YT, Lee SD. Establishment of an animal model of hepatic encephalopathy. J Chin Med Assoc 2000; 63: 263-269
31. Gammal S, Basile AS, Geller D, Skolnick P, Jones EA. Reversal of the behavioral and electrophysiological abnormalities of an animal model of hepatic encephalopathy by benzodiazepine receptor ligands. Hepatology 1990; 11: 371-378
32. Chu CJ, Lee FY, Wang SS, Lu RH, Tsai YT, Lin HC, Hou MC, Chan CC, Lee SD. Hyperdynamic circulation of cirrhotic rats with ascites: role of endotoxin, tumour necrosis factor-a and nitric oxide. Clin Sci 1997; 93: 219-225
33. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Annu Rev Biochem 1986; 55: 69-102
34. Iwai M, Jungermann K. Leukotrienes increase glucose and lactate output decrease flow in perfused rat liver. Biochem Biophys Res Commun 1988; 151: 283-290
35. Busam KJ, Bauer TM, Bauer J, Gerok W, Decker K. Interleukin-6 release by rat liver macrophages. J Hepatol 1990; 11: 367-373
36. Nagai H, Aoki M, Shimazawa T, Yakuo I, Koda A, Kasahara M. Effect of OKY-046 and ONO-3708 on liver injury in mice. Jpn J Pharmac 1989; 51: 191-197
37. Matsukawa R, Takiguchi H. Effect of indomethacin on Ca2+-stimulated adenosine triphosphatase in the synaptic vesicles of rat brain in vitro. Int J Biochem 1982; 14: 713-717
38. Hemker DP, Aiken JW. Actions of indomethacin and prostaglandins E2 and D2 on nerve transmission in the nictitating membrane of the cat. Prostaglandins 1981; 22: 599-611
39. Theodorsson E, Mathe AA, Stenfors C. Brain neuropeptides: tachykinins, neuropeptide Y, neurotensin and vasoactive intestinal polypeptide in the rat brain: modifications by ECT and indomethacin. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14 387-407
40. Old LJ. Tumor necrosis factor (TNF). Science 1985; 230: 630-632
41. Andus T, Bauer J, Gerok W. Effects of cytokines on the liver. Hepatology 1991; 13: 364-375
42. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433-442
43. Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, Ehrich E, Mukhopadhyay S, Daniels B. Rofecoxib, a specific inhibitor of cyclooxygenase-2, with clinical efficacy comparable with that of diclofenac sodium. Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000; 43: 978-987
44. Clemett D, Goa KL. Celecoxib, a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000; 59: 957-980
45. Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, Helgetveit KB, Kress B, Daniels B, Bolognese J, Krupa D, Seidenberg B, Ehrich E. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000; 160: 1781-1787
46. Sinclair SB, Greig PD, Blendis LM, Abecassis M, Roberts EA, Philips MJ, Cameron R, Levy GA. Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report. J Clin Invest 1989; 84; 1063-1069